Key PointsPatience and diversification are emphasized for these speculative picks, given their downside risk and upside potential.

4 High-Risk Stocks Built for Big Returns

Key PointsInvesting in stocks that are trading at low valuations can yield significant returns in the future.

3 Absurdly Cheap Stocks to Buy Before the End of 2026

Key PointsAnalyst opinions and sales projections for weight loss and type 2 diabetes drug VK2735 vary widely, reflecting both promise and uncertainty.

Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.

Key PointsViking Therapeutics will soon enter phase 3 trials with its weight loss pill candidate.

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

(RTTNews) - Viking Therapeutics, Inc. (VKTX) said it has initiated the second part of a clinical trial evaluating oral maintenance dosing regimens of VK2735 in adults with obesity.

Viking Therapeutics Launches Phase 2 Oral VK2735 Maintenance Study 

Key PointsThere’s still plenty of innovation to find within the weight-loss drug space.

Here Are My Top 4 Stocks to Buy in October

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics, Inc. News